US funding cuts have halted critical HIV vaccine trials in South Africa. Professor Glenda Gray headed up one of these trials but now is searching for funding. She explains in conversation with in-depth writer Muhammad Hussain why this $250m annual loss threatens to erase African researchers’ ability to develop vaccines.